Cerapedics files premarket approval application with US FDA for i-FACTOR™ Peptide Enhanced Bone Graft
Application is supported by data from a pivotal clinical trial demonstrating that i-FACTOR bone graft can be used as an alternative to autograft harvesting in certain procedures
Find out moreCerapedics announces closing of venture debt loan from GE Capital
Cerapedics today announced closing of a $9 million venture debt financing from GE Capital, Healthcare Financial Services.
Find out moreCerapedics announces positive results from IDE clinical trial
Results provide significant support to advance i-FACTOR™ Peptide Enhanced Bone Graft for FDA regulatory review.
Find out moreCerapedics to present preliminary outcomes data From i-FACTOR Bone Graft Study at Canaccord Genuity Musculoskeletal Conference
Cerapedics today that preliminary outcomes data from the company's FDA Investigational Device Exemption (IDE) clinical trial for i-FACTOR Peptide Enhanced Bone Graft will be presented at the Canaccord Genuity Muscul…
Find out more
Welcome to Cerapedics
Choose your region
